DMYD-B:STO
Diamyd Medical AB
1,03 SEK
arrow_downward
-1,91%(-0,020) 1D
14 հոկ, 15:46:51 GMT+2 · SEK
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMYD-B...
Open
1,05 SEK
High
1,07 SEK
Low
1,01 SEK
Mkt. cap
155,43 մլն
Avg. vol.
831,77 հզր
Volume
129,73 հզր
52-wk high
17,88 SEK
52-wk low
0,90 SEK
EPS
-1,76 SEK
Shares outstanding
134,00 մլն
No. of employees
42
Open
1,05 SEK
High
1,07 SEK
Low
1,01 SEK
Mkt. cap
155,43 մլն
Avg. vol.
831,77 հզր
Volume
129,73 հզր
52-wk high
17,88 SEK
52-wk low
0,90 SEK
EPS
-1,76 SEK
Shares outstanding
134,00 մլն
No. of employees
42
News stories
From web sources and news partners
Central Oregon Daily
·
47 րոպե առաջ
Wall St set for lower open as hot inflation data fuels rate-hike bets
PR Newswire UK
·
1 ժամ առաջ
Oracle NetSuite Announces Launch of AI-first QuickStart: NYSE Content Update
Reuters
·
28 րոպե առաջ
Wall St opens lower after hot CPI data fuels rate-hike bets
CNBC
·
31 րոպե առաջ
Opening Bell: October 14 2026
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB